These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16869733)

  • 1. Oncogenes come of age.
    Varmus H; Pao W; Politi K; Podsypanina K; Du YC
    Cold Spring Harb Symp Quant Biol; 2005; 70():1-9. PubMed ID: 16869733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
    Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
    Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling.
    Minamoto T; Ougolkov AV; Mai M
    Expert Rev Mol Diagn; 2002 Nov; 2(6):565-75. PubMed ID: 12465453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
    Suda K; Tomizawa K; Mitsudomi T
    Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
    Regales L; Balak MN; Gong Y; Politi K; Sawai A; Le C; Koutcher JA; Solit DB; Rosen N; Zakowski MF; Pao W
    PLoS One; 2007 Aug; 2(8):e810. PubMed ID: 17726540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
    Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW
    Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutations and the terminal respiratory unit.
    Yatabe Y
    Cancer Metastasis Rev; 2010 Mar; 29(1):23-36. PubMed ID: 20135199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenes and the molecular basis of cancer.
    Weinberg RA
    Harvey Lect; 1984-1985; 80():129-36. PubMed ID: 6400654
    [No Abstract]   [Full Text] [Related]  

  • 10. Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
    Chou WC; Huang SF; Yeh KY; Wang HM; Liu MY; Hsieh JJ; Cheung YC; Chang JW
    Jpn J Clin Oncol; 2006 Aug; 36(8):523-6. PubMed ID: 16803841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onc genes and signals of cell growth.
    Vogt PK
    Arzneimittelforschung; 1987 Feb; 37(2A):243-5. PubMed ID: 3566872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
    Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL
    N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancers, oncogenesis and oncogenes].
    Meyer G; Nicoli J
    Med Trop (Mars); 1983; 43(3):217-25. PubMed ID: 6350800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes.
    Bergh JC
    Am Rev Respir Dis; 1990 Dec; 142(6 Pt 2):S20-6. PubMed ID: 2174659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular genetics of human lung cancer.
    Slebos RJ; Rodenhuis S
    Eur Respir J; 1989 May; 2(5):461-9. PubMed ID: 2547647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
    Gazdar AF; Shigematsu H; Herz J; Minna JD
    Trends Mol Med; 2004 Oct; 10(10):481-6. PubMed ID: 15464447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.